Evidence map›Paper›PMID 34830414›Full record

ArticleInternational journal of molecular sciences2021

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.

Marta Gómez-Almería, Sonia Burgaz, Carlos Costas-Insua, Carmen Rodríguez-Cueto, Irene Santos-García, Ignacio Rodríguez-Crespo, Concepción García, Manuel Guzmán, Eva de Lago, Javier Fernández-Ruiz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. New Pharmacological Approaches for Rare Diseases.International journal of molecular sciences · 2023
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Marta Gómez-AlmeríaInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.
Sonia BurgazInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.
Carlos Costas-InsuaCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.ORCID 0000-0003-3446-6899
Carmen Rodríguez-CuetoInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.
Irene Santos-GarcíaInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.ORCID 0000-0002-6266-9530
Ignacio Rodríguez-CrespoCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.
Concepción GarcíaInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.
Manuel GuzmánCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.
Eva de LagoInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.ORCID 0000-0002-6260-3777
Javier Fernández-RuizInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.ORCID 0000-0002-4490-0604
Universidad Complutense de Madrid · ES

Funding

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CB06/05/0089 - CB/06/05/0005 - PI2018/01-1Ministerio de Ciencia, Innovación y Universidades RTI-2018-098885-B-100 and RTI-2018-095311-B-100Programa de Biomedicina - Comunidad de Madrid B2017/BMD-3813
6 · The paper itself

Abstract

In the present study, we investigated the involvement of the chaperone protein BiP (also known as GRP78 or Hspa5), a master regulator of intracellular proteostasis, in two mouse models of neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). To this end, we used mice bearing partial genetic deletion of the BiP gene (BiP

Indexed as

Amyotrophic Lateral SclerosisAnimalsAstrocytesDisease Models, AnimalEndoplasmic Reticulum Chaperone BiPGene Expression RegulationHumansMiceMice, TransgenicMicrogliaMotor NeuronsOxidopamineParkinson DiseaseReceptor, Cannabinoid, CB1Substantia NigraSuperoxide Dismutase-1Endoplasmic Reticulum Chaperone BiPHspa5 protein, mouseOxidopamineReceptor, Cannabinoid, CB1Sod1 protein, mouseSuperoxide Dismutase-1amyotrophic lateral sclerosisBiP interactor proteinBiP+/− micecannabinoidsCB1 receptorsmSOD1 miceParkinson’s diseasespinal cord

Identifiers

PMID34830414
PMCPMC8621319
OpenAlexW3217569112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.